Monthly Prescribing Reference

Onyda XR Extended-Release Suspension Approved for ADHD

Onyda XR should not be substituted for other clonidine products on a mg-per-mg basis. The Food and Drug Administration (FDA) has approved Onyda XR (clonidine hydrochloride) extended-release oral ...
Business Wire

Tris Pharma Secures Additional ex-US Approvals to Expand Global Availability of Quillivant XR and QuilliChew ER for the Treatment of Attention Deficit Hyperactivity Disorder

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and ...
Fierce Healthcare

NextWave Pharmaceuticals Announces Launch of NEXICLON™ XR – First Extended-Release, Once-Daily Clonidine Oral Suspension a

CUPERTINO, Calif.--(BUSINESS WIRE)-- NextWave Pharmaceuticals announced today the launch of NEXICLON ™ XR (clonidine) for the treatment of hypertension. NEXICLON XR provides for once-daily dosing, in ...
Business Wire

Tris Pharma’s Once-Daily ADHD Medication, ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, Now Available in the United States

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and ...
FiercePharma

Pfizer Announces Availability Of Quillivant XR™ (methylphenidate hydrochloride) CII For Extended-Release Oral Suspension In The United States

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that Quillivant XR™ (methylphenidate hydrochloride) CII for extended-release oral suspension is now available in the U.S. for the ...